• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Shareholders sue Stereotaxis after dismal Q2 results

Shareholders sue Stereotaxis after dismal Q2 results

October 14, 2011 By MassDevice staff

Stereotaxis

Shareholders of Stereotaxis Inc. (NSDQ:STXS) are suing the company and its management, accusing them of misleading investors about its backlog of orders, even as senior executives take voluntary pay cuts through 2013.

The lawsuit alleges that the St. Louis-based company, CEO Michael Kaminski and former CFO Daniel Johnston misled investors about its market position, claiming a large backlog of orders for its Niobe and Odyssey systems.

The case was spurred by the nosedive STXS shares took in August, after the company released dismal second-quarter numbers and suspended its 2011 guidance. Share prices sank 58 percent from an August 8 close of $2.85 to $1.19 at the end of the day August 10 (Stereotaxis shares were trading flat at $1.12 today as of about 3:30 p.m.). The poor performance prompted Johnston’s ouster; he was replaced by Samuel Duggan earlier this month.

Sign up to get our free newsletters delivered straight to your inbox

"The backlog of orders that defendants had boasted about and the ‘robust market’ were mere illusions created by defendants, as the sales of the Niobe and Odyssey systems were fast deteriorating," according to the lawsuit. "As a result of defendants’ false statements, Stereotaxis’s stock traded at artificially inflated prices … reaching a high of $4.24 per share on April 5, 2011.

"Stereotaxis’s actual performance in executing its projected financial results, however, fell woefully short of defendants’ false statements," according to the suit. "On August 8, 2011, Stereotaxis issued a press release announcing financial results for the second quarter of fiscal year 2011 that showed that the Company was performing well below expectations, as revenue had declined 22.7 percent from $15 million for the second quarter of 2010. Stereotaxis also reported that its net loss for the second quarter of 2011 was $9.7 million, or $0.18 per share, compared to a net loss of $3.9 million, or $0.08 per share, reported for the second quarter of 2010."

In a move that may be related, Kaminski and the rest of the company’s senior management agreed to significant pay cuts, according to a regulatory filing. Here’s how the cuts break down:

  • Michael Kaminski, CEO: $352,000 (-16%)
  • Douglas Bruce, COO & CTO: $292,500 (10%)
  • Frank Cheng, SVP, marketing & business development; GM, Odyssey business: $256,500 (10%)
  • David Giffin, VP, human resources: $180,000 (10%)
  • Karen Witte Duros, SVP, general counsel & secretary: $243,000 (10%)

Noticeably absent from the list is Duggan, which might indicate that the cuts are related to the second-quarter results. Stereotaxis said it wants to keep the executives on board, "in order to ensure the timely implementation of the company’s strategic plans," and thus granted shares of restricted stock to each, vesting in 2013.

Filed Under: Legal News, News Well, Surgical Robotics, Wall Street Beat Tagged With: Stereotaxis

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy